SERG Technologies

What SERG Technologies does

SERG Technologies Ltd is a London-based digital health company founded in 2019 that develops AI-powered wearable sensing technology for Parkinson's disease care. Its flagship product, StimSense, combines a proprietary 2x IMU-MMG wearable sensor (dual Inertial Measurement Units plus dual Mechanomyogram channels) with proprietary machine-learning algorithms to objectively quantify cardinal Parkinsonian motor symptoms (tremor, bradykinesia, rigidity) and automate Deep Brain Stimulation (DBS) programming parameter optimisation. The technology is edge-deployed and designed to integrate with the programming environments of the three largest DBS manufacturers — Medtronic, Abbott, and Boston Scientific. In a 2024 pilot with Boston Scientific, StimSense reduced average DBS programming time by 74% (from 270 to 70 minutes) while maintaining clinical outcomes comparable to standard-of-care and achieving a median correlation of r=0.74 with specialist clinician assessments.

The company sells to enterprise healthcare customers — NHS hospitals, private neurology clinics, and DBS specialty centres — via a direct B2B sales motion targeting neurologists and DBS programmers. Its commercial offering centres on subscription-based enterprise licensing of the StimSense software platform (quote-based, annual billing cadence, no public pricing), supplemented by the broader SERG Platform covering symptom rating, medication response monitoring, and therapy programme planning. A 14-15 person team led by CEO Dr Samuel Wilson, COO Diana Darko, CFO Ewan Phillips, and CBO Dr Christos Kapatos executes the work, supported by an advisory board of senior UK neurologists and biomechatronics academics from City St. George's, Imperial College London, St George's Hospital, and Charing Cross Hospital. To date, the company has raised approximately $2.4M across two funding rounds (a 2019 seed led by Velocity Partners and a July 2022 round led by Mercia Asset Management), with no disclosed revenue.

Name

SERG Technologies

Legal name

SERG Technologies Ltd

Website

https://sergtechnologies.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

SERG Technologies is a London-based digital health company developing StimSense, an AI-powered wearable platform using proprietary 2x IMU-MMG sensors to automate Deep Brain Stimulation programming for Parkinson's patients. It sells enterprise software to NHS hospitals, private neurology clinics, and DBS manufacturers.

Ownership category

akta.pro rank

Product category

Neurological Digital Health Software

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

akta.pro secondary industry

Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms (HLALABAK)

Keywords

• Wearable health sensors
• DBS programming software
• Parkinson's disease management
• Motor symptom assessment
• Digital health platform

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain, Infrastructure

Revenue model

1. StimSense Software Platform: SaaS/platform revenue model for the StimSense software solution sold to healthcare institutions for use in DBS programming workflows. Revenue derived from licensing the software platform to hospitals and clinics that perform DBS procedures. Potential for per-session or subscription-based pricing tied to usage volume in clinical settings.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

SERG Technologies develops and sells StimSense, an AI-powered wearable sensing platform that objectively quantifies Parkinsonian motor symptoms (tremor, bradykinesia, rigidity) and automates Deep Brain Stimulation (DBS) programming for neurologists and DBS specialty centers. The offering pairs proprietary 2x IMU-MMG wearable sensors with edge-deployed algorithms and integrates with major DBS manufacturer ecosystems (Medtronic, Abbott, Boston Scientific) to reduce programming session times from 4-5 hours to under 90 minutes.

Product overview

SERG Technologies offers a unified digital health platform for Parkinson's care built around its core products: StimSense for automated DBS programming, the SERG Platform for comprehensive symptom management, and proprietary 2x IMU-MMG wearable sensors for physiological data capture. The platform integrates symptom rating, medication response monitoring, and therapy program planning, while the development software suite supports signal acquisition, cloud storage, and AI-enabled testing. StimSense serves as the flagship product for accelerating DBS programming through objective symptom scoring.

Differentiator

Problem solved

Functional benefit

Brands

• StimSense: Automated assessment tool for DBS (Deep Brain Stimulation) programming that uses wearable sensors and AI algorithms to quantify Parkinsonian motor symptoms and accelerate programming sessions.

Products and services

• StimSense
• SERG Platform
• 2x IMU-MMG Wearable Sensor
• SERG Development Software

Quantifiable outcome

• 74% reduction in DBS programming time (from 270 minutes to 70 minutes)
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability5 records

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Boston ScientificcoreStrategic or Co-development PartnerCompleted pilot study in collaboration with Boston Scientific to test StimSense inside live DBS programming sessions. The aim was to evaluate its impact on session efficiency, decision making and clinical outcomes. Results showed significant time savings and maintained clinical outcomes comparable to standard-of-care.
• City St. George's, University of LondoncoreStrategic or Co-development PartnerProf. Francesca Morgante (Professor of Neurology, Eleanor Peel Chair) serves on the SERG Technologies Advisory Board, providing clinical neurology expertise and academic institutional partnership.
• Imperial College LondoncoreStrategic or Co-development PartnerProf. Ravi Vaidyanathan (Professor in Biomechatronics) serves on the Advisory Board, contributing biomechatronics expertise and academic research partnership.
• St George's HospitalcoreStrategic or Co-development PartnerDr Fahd Baig (Consultant Neurologist) serves on the Advisory Board, providing clinical neurology expertise and hospital partnership for product development.
• Charing Cross HospitalcoreStrategic or Co-development PartnerDr Yen Tai serves on the Advisory Board, providing clinical neurology expertise from this NHS hospital setting.
• Red MedtechminorImplementation/ SI/ Consulting PartnerProf. Laurie Rowe serves as Regulatory Consultant through Red Medtech, providing regulatory affairs expertise for medical device compliance.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Global Kinetics Corporation: Developer of the Personal KinetiGraph (PKG) wearable watch for objective measurement of Parkinson's motor symptoms. Direct competitor in Parkinson's wearable symptom quantification, with FDA-cleared technology used in clinical and trial settings.
• Great Lakes NeuroTechnologies: Maker of Kinesia and Kinesia One systems for objective motor assessment in Parkinson's and movement disorders using wearable sensors. Direct competitor in sensor-based Parkinson's symptom scoring with FDA-cleared products used in DBS programming and clinical trials.
• ClearSky Medical Diagnostics: Developer of PD-Monitor, LID-Monitor, and Essential Tremor Monitor devices that use wearable sensors and machine learning to assess Parkinson's and levodopa-induced dyskinesia symptoms. Direct competitor in Parkinson's wearable monitoring for clinical decision support.
• APDM Wearable Technologies: Provider of Opal and Mobility Lab wearable inertial sensor platforms for movement disorder quantification in clinical trials and routine care. Direct competitor in wearable Parkinson's and movement-disorder assessment, now part of Clario's eCOA portfolio.
• BioSensics: Developer of wearable sensors and algorithms for Parkinson's disease, fall risk, and movement disorders used in clinical trials and remote monitoring. Direct competitor in wearable Parkinson's assessment with overlapping algorithmic and sensing capabilities.

Emerging players

• Rune Labs: StriveStudy and brain-computer-interface platform for Parkinson's that combines Apple Watch and Medtronic Percept PC sensing data for clinical decision support. Emerging player with overlapping Parkinson's sensing strategy and explicit DBS manufacturer partnership.
• McRoberts: Maker of MoveMonitor and DynaPort wearable systems for objective activity and gait measurement in Parkinson's and other chronic conditions. Emerging player in movement-disorder wearable sensing with comparable clinical research applications to SERG.

Broad incumbents

• Medtronic: World-leading DBS system manufacturer (Activa PC, Percept PC with BrainSense) that controls the programming environment StimSense integrates with. Broad incumbent that could build or acquire competing objective programming automation, and a critical channel partner for commercialization.
• Boston Scientific: DBS system manufacturer (Vercise family) and named SERG pilot partner. Broad incumbent with direct visibility into StimSense's clinical value and the strategic option to internalize, license, or compete with the technology.
• Abbott: DBS system manufacturer (Infinity, Liberta RC) and named StimSense integration partner. Broad incumbent with the installed base and engineering scale to develop in-house alternatives or become SERG's distribution channel for clinicians using Abbott DBS hardware.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/serg-technologies
• Instagraminstagram.com/serg_technologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SERG Technologies